{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:30:34Z","timestamp":1707525034970},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,10]]},"DOI":"10.7759\/cureus.38833","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:47:03Z","timestamp":1683730023000},"source":"Crossref","is-referenced-by-count":0,"title":["End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir"],"prefix":"10.7759","author":[{"given":"Attiya S","family":"Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qaiser","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehwish","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.99625","article-title":"Sofosbuvir and ribavirin combination therapy response in various hepatitis C virus genotypes in Peshawar, Khyber Pakhtunkhwa","volume":"13","author":"Haider SA","year":"2020","unstructured":"Haider SA, Ahmad B, Ali S, Haider A, Bashir S, Mahmood N. Sofosbuvir and ribavirin combination therapy response in various hepatitis C virus genotypes in Peshawar, Khyber Pakhtunkhwa. Jundishapur J Microbiol. 2020, 13:10.5812\/jjm.99625","journal-title":"Jundishapur J Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01837-y","article-title":"Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan","volume":"21","author":"Huang YT","year":"2021","unstructured":"Huang YT, Hsieh YY, Chen WM, et al.. Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol. 2021, 21:259. 10.1186\/s12876-021-01837-y","journal-title":"BMC Gastroenterol"},{"key":"ref3","unstructured":"Fact sheets. hepatitis C. (2022). Accessed: October 14, 2022: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30036-X","article-title":"The cost of eliminating hepatitis C in Pakistan","volume":"8","author":"Abbas Z","year":"2020","unstructured":"Abbas Z, Abbas M. The cost of eliminating hepatitis C in Pakistan. Lancet Glob Health. 2020, 8:323-4. 10.1016\/S2214-109X(20)30036-X","journal-title":"Lancet Glob Health"},{"key":"ref5","unstructured":"Global hepatitis report 2017. (2017). Accessed. January 11, 2023: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789?sequence=1."},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V78.12.3142.3142","article-title":"Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia","volume":"78","author":"Casato M","year":"1991","unstructured":"Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood. 1991, 78:3142-7.","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310421","article-title":"Hepatitis C virus treatment in the real world: optimising treatment and access to therapies","volume":"64","author":"Zoulim F","year":"2015","unstructured":"Zoulim F, Liang TJ, Gerbes AL, et al.. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015, 64:1824-33. 10.1136\/gutjnl-2015-310421","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2018.31","article-title":"Efficacy and safety of generic daclatasvir+sofosbuvir\u00b1ribavirin in treatment of genotype 3 infected hepatitis C patients - a real life experience from Pakistan","volume":"4","author":"Umar M","year":"2018","unstructured":"Umar M, Akhter TS, Sadiq J, Saleem S, Khokhar S. Efficacy and safety of generic daclatasvir+sofosbuvir\u00b1ribavirin in treatment of genotype 3 infected hepatitis C patients - a real life experience from Pakistan. Hepatoma Res. 2018, 4:10.20517\/2394-5079.2018.31","journal-title":"Hepatoma Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy V","year":"2016","unstructured":"Leroy V, Angus P, Bronowicki JP, et al.. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016, 63:1430-41. 10.1002\/hep.28473","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00038","article-title":"Efficacy and safety of daclatasvir in hepatitis C: an overview","volume":"4","author":"Gamal N","year":"2016","unstructured":"Gamal N, Gitto S, Andreone P. Efficacy and safety of daclatasvir in hepatitis C: an overview. J Clin Transl Hepatol. 2016, 4:336-44. 10.14218\/JCTH.2016.00038","journal-title":"J Clin Transl Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v14.i4.647","article-title":"Revolution in the diagnosis and management of hepatitis C virus infection in current era","volume":"14","author":"Hanif FM","year":"2022","unstructured":"Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol. 2022, 14:647-69. 10.4254\/wjh.v14.i4.647","journal-title":"World J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.894460","article-title":"Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals","volume":"13","author":"Mushtaq S","year":"2022","unstructured":"Mushtaq S, Hashmi AH, Khan A, Asad Raza Kazmi SM, Manzoor S. Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals. Front Pharmacol. 2022, 13:10.3389\/fphar.2022.894460","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2014.08.004","article-title":"Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India","volume":"4","author":"Gupta V","year":"2014","unstructured":"Gupta V, Kumar A, Sharma P, Tyagi P, Bansal N, Singla V, Arora A. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India. J Clin Exp Hepatol. 2014, 4:287-92. 10.1016\/j.jceh.2014.08.004","journal-title":"J Clin Exp Hepatol"},{"key":"ref14","unstructured":"Optimizing medicines and treatment regimens for hepatitis C patients in Pakistan. (2018). Accessed. May 1, 2023: https:\/\/www.researchgate.net\/publication\/327361674_Optimizing_medicines_and_treatment_regimens_for_hepatitis_C_patien...."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.51253\/pafmj.v72i3.4470","article-title":"Efficacy of sofosbuvir and daclatasvir in achieving the end treatment response and sustained viral response in Patients infected with hepatitis C virus genotype 3","volume":"72","author":"Ullah Z","year":"2022","unstructured":"Ullah Z, Khan SZ, Lodhi H, Khan H, Hidayat R, Ahmed M. Efficacy of sofosbuvir and daclatasvir in achieving the end treatment response and sustained viral response in Patients infected with hepatitis C virus genotype 3. Pak Armed Forces Med J. 2022, 72:1074-7. 10.51253\/pafmj.v72i3.4470","journal-title":"Pak Armed Forces Med J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.35.2.637","article-title":"Daclatasvir plus sofosbuvir with or without ribavirin in patients with chronic hepatitis C genotype 3a in Pakistani population - a real world experience","volume":"35","author":"Butt Z","year":"2019","unstructured":"Butt Z, Shah SM. Daclatasvir plus sofosbuvir with or without ribavirin in patients with chronic hepatitis C genotype 3a in Pakistani population - a real world experience. Pak J Med Sci. 2019, 35:409-13. 10.12669\/pjms.35.2.637","journal-title":"Pak J Med Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.37.7.4627","article-title":"Effectiveness of sofosbuvir and daclatasvir in treatment of hepatitis C: an experience of tertiary care hospital in Karachi","volume":"37","author":"Butt N","year":"2021","unstructured":"Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of sofosbuvir and daclatasvir in treatment of hepatitis C: an experience of tertiary care hospital in Karachi. Pak J Med Sci. 2021, 37:2014-9. 10.12669\/pjms.37.7.4627","journal-title":"Pak J Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.550205","article-title":"Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir\/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan","volume":"11","author":"Mushtaq S","year":"2020","unstructured":"Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir\/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan. Front Pharmacol. 2020, 11:10.3389\/fphar.2020.550205","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-018-1066-8","article-title":"Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study","volume":"15","author":"Tao YC","year":"2018","unstructured":"Tao YC, Deng R, Wang ML, et al.. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. Virol J. 2018, 15:10.1186\/s12985-018-1066-8","journal-title":"Virol J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1156","article-title":"Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease\/cirrhosis in a real-world cohort","volume":"2","author":"Kwo P","year":"2018","unstructured":"Kwo P, Fried MW, Reddy KR, et al.. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease\/cirrhosis in a real-world cohort. Hepatol Commun. 2018, 2:354-63. 10.1002\/hep4.1156","journal-title":"Hepatol Commun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.03.025","article-title":"HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: the ITAL-C network study","volume":"49","author":"Ippolito AM","year":"2017","unstructured":"Ippolito AM, Milella M, Messina V, et al.. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: the ITAL-C network study. Dig Liver Dis. 2017, 49:1022-8. 10.1016\/j.dld.2017.03.025","journal-title":"Dig Liver Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002287","article-title":"Safety and efficacy of sofosbuvir\/ledipasvir and sofosbuvir\/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis","volume":"33","author":"El Kassas M","year":"2021","unstructured":"El Kassas M, Abdeen N, Omran D, et al.. Safety and efficacy of sofosbuvir\/ledipasvir and sofosbuvir\/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis. Eur J Gastroenterol Hepatol. 2021, 33:877-82. 10.1097\/MEG.0000000000002287","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-022-00174-3","article-title":"Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B","volume":"12","author":"El Raziky M","year":"2022","unstructured":"El Raziky M, Hamdy S, Hamada Y,  Abdelaziz NM, Hassany M, Doss W, Zakaria Z . Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B. Egypt Liver J. 2022, 12:10.1186\/s43066-022-00174-3","journal-title":"Egypt Liver J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S160593","article-title":"Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection","volume":"11","author":"Ahmed OA","year":"2018","unstructured":"Ahmed OA, Elsebaey MA, Fouad MH, et al.. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018, 11:441-5. 10.2147\/IDR.S160593","journal-title":"Infect Drug Resist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/medicina54050080","article-title":"Current status of direct acting antiviral agents against hepatitis C virus infection in Pakistan","volume":"54","author":"Khaliq S","year":"2018","unstructured":"Khaliq S, Raza SM. Current status of direct acting antiviral agents against hepatitis C virus infection in Pakistan. Medicina (Kaunas). 2018, 54:10.3390\/medicina54050080","journal-title":"Medicina (Kaunas)"},{"key":"ref26","article-title":"Diagnosis, management and prevention of hepatitis C in Pakistan 2017","volume":"28","author":"Umar M","year":"2016","unstructured":"Umar M, Khaar MT, Akhter TS, et al.. Diagnosis, management and prevention of hepatitis C in Pakistan 2017. J Ayub Med Coll Abbottabad. 2016, 28:839-82.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.331.12352","article-title":"Initial results of efficacy and safety of sofosbuvir among Pakistani population: a real life trial - hepatitis eradication accuracy trial of sofosbuvir (HEATS)","volume":"33","author":"Azam Z","year":"2017","unstructured":"Azam Z, Shoaib M, Javed M, Sarwar MA, Shaikh H, Khokhar N. Initial results of efficacy and safety of sofosbuvir among Pakistani population: a real life trial - hepatitis eradication accuracy trial of sofosbuvir (HEATS). Pak J Med Sci. 2017, 33:48-52. 10.12669\/pjms.331.12352","journal-title":"Pak J Med Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.331.12163","article-title":"Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?","volume":"33","author":"Sarwar S","year":"2017","unstructured":"Sarwar S, Khan AA. Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?. Pak J Med Sci. 2017, 33:37-41. 10.12669\/pjms.331.12163","journal-title":"Pak J Med Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.334.12785","article-title":"Rapid virological & end treatment response of patients treated with sofosbuvir in chronic hepatitis C","volume":"33","author":"Siddique MS","year":"2017","unstructured":"Siddique MS, Shoaib S, Saad A, Iqbal HJ, Durrani N. Rapid virological & end treatment response of patients treated with sofosbuvir in chronic hepatitis C. Pak J Med Sci. 2017, 33:813-7. 10.12669\/pjms.334.12785","journal-title":"Pak J Med Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i44.7899","article-title":"Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: a prospective study","volume":"23","author":"Iqbal S","year":"2017","unstructured":"Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: a prospective study. World J Gastroenterol. 2017, 23:7899-905. 10.3748\/wjg.v23.i44.7899","journal-title":"World J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/152915-end-treatment-response-and-sustained-viral-response-in-patients-with-hepatitis-c-virus-receiving-sofosbuvir-and-daclatasvir","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:28Z","timestamp":1707508768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/152915-end-treatment-response-and-sustained-viral-response-in-patients-with-hepatitis-c-virus-receiving-sofosbuvir-and-daclatasvir"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.38833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}